Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ENDRA Life Sciences (NDRA) Cash from Financing Activities (2016 - 2021)

ENDRA Life Sciences (NDRA) has disclosed Cash from Financing Activities for 6 consecutive years, with $321076.0 as the latest value for Q4 2021.

  • Quarterly Cash from Financing Activities fell 94.24% to $321076.0 in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $13.4 million through Dec 2021, up 12.86% year-over-year, with the annual reading at $5.7 million for FY2025, 26.59% down from the prior year.
  • Cash from Financing Activities for Q4 2021 was $321076.0 at ENDRA Life Sciences, down from $496606.0 in the prior quarter.
  • The five-year high for Cash from Financing Activities was $12.6 million in Q1 2021, with the low at $39238.0 in Q1 2020.
  • Average Cash from Financing Activities over 5 years is $3.9 million, with a median of $2.5 million recorded in 2019.
  • Peak annual rise in Cash from Financing Activities hit 31970.75% in 2021, while the deepest fall reached 94.24% in 2021.
  • Over 5 years, Cash from Financing Activities stood at $8.5 million in 2017, then dropped by 9.41% to $7.7 million in 2018, then dropped by 24.45% to $5.8 million in 2019, then decreased by 4.67% to $5.6 million in 2020, then plummeted by 94.24% to $321076.0 in 2021.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $321076.0, $496606.0, and $12.6 million for Q4 2021, Q3 2021, and Q1 2021 respectively.